NRCAM is recurrently dysregulated in lower-grade gliomas through CNVs and DNA methylation, both of which stratify patient survival. Together with previously reported splicing deregulation, these data suggest that NRCAM functions as a multilayered regulator of glioma progression. NRCAM methylation may represent a potential prognostic biomarker, while therapeutic modulation of NRCAM warrants further investigation.
Lehrer et al. (Thu,) studied this question.